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THE IRISH PHARMACEUTICAL INDUSTRY OVER THE 
BOOM PERIOD AND BEYOND 
 
Abstract 
 
The pharmaceutical industry has been one of the strongest performing sectors of the 
Celtic Tiger era. During the past two decades, employment growth in the sector has 
been strong and continuous, even when, in recent years, employment in other 
manufacturing sectors has been contracting. Although positive in itself, from a 
dynamic regional development perspective it is important to explore the qualitative 
changes in the types of activities that are conducted in Ireland. Adopting a global 
production network approach, the paper examined Ireland’s changing role in global 
production networks within the pharmaceutical industry, focussing on the different 
components of manufacturing and R&D. The analysis shows that Ireland’s 
involvement in manufacturing has shifted in the direction of relatively higher value 
generating activities. Within R&D, although the level of value creation has increased 
substantially, Ireland’s involvement remains concentrated in the (relatively) lower 
value generating activities of the global R&D network. In addition, the sector remains 
strongly dominated by foreign direct investment so that a large share of the created 
value is not captured within Ireland 
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1. Introduction 
 
The pharmaceutical sector is of substantial importance to Ireland.  It accounts for 
almost 16 percent of industrial exports and some 5 percent of manufacturing 
employment, and is one of the highest-skill sectors of manufacturing industry. Yet, 
the developmental aspects of the sector have been little researched. This paper 
provides a detailed account of the dynamics of the Irish sector over recent decades.  
The paper engages principally with the regional development literature and employs 
the Global Production Network (GPN) framework that seeks to shed light on the 
relation between economic integration, globalisation and regional development 
(Dicken et al., 2001; Henderson et al., 2002; Yeung et al., 2001). This framework 
proposes that the globalisation of production networks of firms and institutions 
integrates economies in ways which have important implications for development. We 
analyse Ireland’s changing role in the global production networks of the 
pharmaceutical industry, notably with respect to R&D and manufacturing. 
 
The analysis is based on statistical data from national and international institutions; on  
52 semi-structured face-to-face interviews with senior staff at 13 selected 
pharmaceutical companies, and on a 2006 email survey of all (80) existing 
pharmaceutical establishments. 
 
The paper begins with a discussion of the role of global production networks as 
discussed in the regional development literature. This is followed by an account of the 
development of the Irish pharmaceutical industry. Following a description of the 
value chain of the industry, the paper presents a detailed investigation of the 
qualitative changes in Ireland’s role in manufacturing (of both active ingredients and 
drug formulations) and various elements of the R&D cycle (including discovery, 
clinical trials and process development. The paper ends with some concluding 
comments. 
 
2. Global Production Networks 
 
Geographers have been active participants in the analysis of regional economic 
development. Following the seminal work of Piore and Sabel (1984), many studies 
emphasised the role of internal production linkages, local institutions and indigenous 
firms. Another body of work has concentrated on external linkages, notably the 
impact of subsidiaries of multinational enterprises on local and national development, 
and some of this work has taken a more dynamic perspective by analysing the 
developmental impact of industrial change and the related organisational dynamics of 
MNEs (Yeung, 2000; Hudson, 1994; Hudson, 1997; Phelps, 1993; Pike, 1998).  
 
In search for an overall framework for understanding issues of global integration and 
local economic development, Gerreffi and others developed the Global Commodity 
Chain (GCC) framework (Gerreffi, 2001; Gereffi, and Korzeniewicz, 1994; Bair and 
Gereffi, 2001), which privileges the dynamics of global industries and the role of 
external linkages in understanding regional economic development. Building on the 
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GCC concept, Dicken et al. (2001) propose a global production network (GPN) 
framework (see also Henderson et al., 2002; Yeung et al., 2001), which emphasises 
the role of the firm and networks of firms. The idea is that production networks of 
firms and institution have become increasingly global and integrate economies in 
ways which have important implications for development. An understanding of the 
economic development implications for regions requires a study of the dynamics of  
“what [lead-] firms do, where they do it, why they do it, why they are allowed to do it 
and how they organise the doing of it across different geographic scales” (Henderson 
et al. 2002, p. 5).  
 
The GPN perspective explicitly accords a degree of power and autonomy to domestic 
firms, governments and institutions whose actions can influence the economic 
outcomes of the network processes in their own locations. Furthermore, the GPN 
framework more explicitly acknowledges that input-output flows can be organised 
horizontally and diagonally as well as vertically.  
 
The GPN perspective directs attention to the networks of firms involved in the whole 
range of activities linked to a given product (including R&D, design, production, 
marketing and other services), the way these are organised globally, the way this 
global organisation is influenced by governments and institutions, and the overall 
implications for upgrading and development. One of the central concepts in the 
analysis of the inter-organisational connections and their relations to economic 
development of particular localities is value; specifically the way in which it is created 
and the extent to which it is captured in various locations. Part of the contribution of 
the present paper is to analyse Ireland`s changing role in global production networks 
and what this means in terms of value creation. Before this, we present an account of 
Ireland`s emergence as an important player in the global pharmaceutical industry.  
 
 
3. The Growth of the Irish Pharmaceutical Industry 
 
The development of the Irish pharmaceutical industry has been, and continues to be, a 
major international success story. Until the 1960s there was virtually no 
pharmaceutical industry in Ireland (Galvin, 1998). The post-independence autarkic 
economic development policies, including the Control of Manufacturers Act 
(designed to keep the ownership of industry in native hands), offered little incentive 
for foreign companies to invest in Ireland (White, 2000b), while the manufacturing of 
most pharmaceutical products was too sophisticated and capital-intensive for 
indigenous players. The first substantial investments by foreign pharmaceutical 
companies followed rapidly on from the shift towards more outward–looking 
economic policies towards the end of the 1950s (Van Egeraat, 2006; Van Egeraat and 
Breathnach, 2007). However, the sector really took off in the 1970s following the 
IDA`s adoption of fine chemicals as one of its target sectors (Childs, 1996). This led 
to a series of manufacturing investments, notably by US and UK-based companies.  
 
Figures 1 and 2 chart the growth in employment in the pharmaceuticals sector in 
Ireland in the periods 1979-1991 and 1991-2005 respectively, using CSO data. There 
is a structural break in the data as the industrial classification system changed in 1991.  
At the beginning of the period, the sector accounted for around 2,500 jobs and just 
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one percent of manufacturing employment.  By 2005, employment numbers in the 
now more narrowly defined sector had grown to 11,000 and the sector now accounted 
for some five percent of Irish manufacturing employment. While overall 
manufacturing employment has fluctuated over the last decade, recording largely 
similar numbers for 1995 and 2005, the pharma sector is one of the few to have 
recorded almost continuous employment growth over the period (apart from what 
might be viewed as a positive blip in 2002). 
 
The Forfás employment survey records far higher employment numbers for the sector 
than the CSO figures. Using this data set Van Egeraat (2006) shows that in 2003 the 
industry already employed 19,500 workers (see also Figure 3). Again, the data paint a 
picture of strong and nearly continuous employment growth since the early 1970s – 
even after 2001, when employment in most other manufacturing sectors contracted.   
 
The continuing growth of employment in the Irish pharmaceutical industry, even at a 
time when employment in other manufacturing industries started to decline has 
significantly increased the relative importance of the pharmaceutical industry. Table 1 
shows how the share of the pharmaceutical industry in total manufacturing 
employment has increased from under 2 per cent in 1990 to 5.2 percent in 2005, by 
far the highest figure for any OECD economy. 
 
The quality of the jobs further increases the importance of the industry. 
Pharmaceuticals are by all available measures one of the highest-skill sectors within 
Irish manufacturing.  Skill intensity is typically proxied either by the share of third-
level graduates in sectoral employment or, more directly, by wage levels per 
employee.  Table 2 shows that the broad Chemicals sector (of which pharma is a 
significant component), records the highest skill levels, using the share of third-level 
graduates as indicator, while Table 3 shows that this sector, with the lower-tech 
Rubber and Plastics segment stripped out, records the highest wage levels, though 
wages in Pharma are marginally below those in the remainder of the sector. 
 
Ireland has become an important exporter of pharmaceutical products. Table 4 
displays the shares of global pharmaceutical exports recorded for various countries 
over the period 1965-2005.  The shares emanating from traditional pharma exporting 
countries such as the US, the UK, Switzerland and Germany have all substantially 
shrunk.  In contrast, Ireland’s market share in pharmaceuticals has grown 
substantially, particularly over the Celtic Tiger era and beyond. The expansion of 
Ireland’s market share is all the more remarkable in that it has not been replicated by 
other non-traditional exporting countries, with the exception of Belgium.  
 
India and China, for example, are yet to become major global exporters of 
pharmaceuticals.  India’s share of global pharma exports has hovered around 1 
percent since 1980 while exports by the Chinese pharmaceutical industry are even less 
important, accounting for only 0.5 percent of global exports in 2005.  Malaysian and 
South Korean pharma exports are also insignificant, while, perhaps surprisingly, Israel 
and Singapore hover at around only 1 percent.   
 
In 2006, Irish pharmaceutical exports were worth around $17 billion.  This accounted 
for almost 16 percent of Irish industrial exports and over 6 percent of world 
pharmaceutical exports, while Irish industrial exports overall comprised less than 1 
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percent of world industrial exports. The Irish industry’s growth has been largely based 
on foreign direct investment however. In 2003, the 95 subsidiaries of foreign 
companies accounted for 93 per cent of pharmaceutical employment and virtually all 
employment in the drug substance sub-sector. Indigenous operations remained 
relatively small with only seven indigenous companies employing more than 50 staff 
(Van Egeraat and Breatnach, 2007). 
 
While pharma imports came to only around $2 billion1, it must be recognised that a 
large share of the value of the exports is not added in Ireland. Apart from the import 
of raw and intermediate materials, all of Ireland’s foreign-owned manufacturing 
sectors make substantial payments to their overseas parent companies in the form of 
royalties and licence fees and payments for miscellaneous business services. In 
addition there is a widespread suspicion that the country’s trade surplus in 
pharmaceuticals is inflated by the behaviour of corporations who face an incentive to 
shift profits to low-corporation-tax locations.  One way in which this can be done is 
through the manipulation of ‘transfer prices’ (the prices charged for the transfer of 
goods and services between a parent company and its foreign affiliates). Some 
indications of the possible extent of transfer pricing in the Irish pharmaceuticals case 
are suggested by the data in Table 5.  Gross value added per person employed in the 
sector in Ireland is more than double the EU15 average and one and a half times the 
level prevailing in the UK sector, while the share of personnel costs in production is 
substantially lower than in either of the other geographic entities. 
 
Profit outflows from Ireland’s FDI-intensive pharmaceutical sector are very 
substantial as many foreign parents take substantial dividend payments from their 
Irish units (Beesley, 2005). Thus although much value may appear to be created in 
Ireland, a large share of this value is not captured in Ireland. 
 
We have seen that the level of economic activity in the Irish pharmaceutical industry 
has increased substantially over recent decades and that Ireland has become one of the 
main pharmaceutical exporters. The remainder of the paper will analyse in more detail 
Ireland’s changing role in the global production networks of the pharmaceutical 
industry.   
 
4. The value chain of the pharmaceutical industry 
 
A basic model of the value chain of the pharmaceutical industry includes the 
following segments: discovery, product development or clinical trials, process R&D, 
active ingredient manufacturing, drug product (formulation) manufacturing; sales and 
marketing; and corporate functions. Discovery covers the initial product R&D 
activities, i.e. research into the causes of diseases and the identification of compounds 
that have a pharmacological effect. Product development includes the further 
development of these compounds, and notably their testing in pre-clinical and clinical 
trials. Process R&D is concerned with the development of safe and efficient 
manufacturing processes at commercial scale. Manufacturing encompasses the 
production of raw materials, intermediates, active ingredients and drug products 
                                                 
1 Data from intracen.org (the International Trade Centre, a joint facility of UNCTAD and the WTO).  
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(formulations). All these activities are supported by corporate functions such as 
strategic management, finance, supply chain management etc. 
 
The various segments account for different levels of value creation. It is difficult (and 
not the aim of this paper) to quantify these levels, partly because the concept is not 
easy to operationalise. (Henderson et al., 2002, for example define value as “a 
combination of the Marxian notion of surplus value with more orthodox notions of 
economic rent”).  One option is to apply the notion of value-added, which is 
occasionally employed by the original proponents of the GPN approach (Henderson et 
al., 2002, p. 28). Value-added refers to the additional value of an output over the cost 
of the inputs used to produce it from the previous stage of production. High value 
added is generally related to high value creation with a strong positive impact on 
economic development.  
 
Discovery, clinical trials and corporate functions are generally considered to be high 
value added activities. Manufacturing is often seen as a relatively lower value added 
activity, though the level of value added in active ingredients is higher than in drug 
formulations. Process R&D and sales and marketing are in turn generally 
characterised as medium-level. A complementary way to account for the level of 
value creation is to consider the skill/education levels and the number of highly 
skilled staff involved in the activities in a particular locality. 
 
In reality, as will become clear, most of the segments of the value chain involve a 
number of activities with different characteristics in terms of value creation. The 
remainder of this paper analyses Ireland’s changing role in global production 
networks, focussing on manufacturing of active ingredients and drug formulations, 
and R&D in the areas of discovery, clinical trials and process development. 
 
 
5. Manufacturing 
 
Pharmaceutical manufacturing includes the manufacture of active ingredients (the 
drug substance), drug formulations (the actual tablet, capsule or injection material) 
and inputs to these items. Active ingredients, which are responsible for the 
pharmacological effect, are the most important ingredients of the drug formulation. 
Drug formulation and active ingredients involve different manufacturing processes. 
Active ingredients can be manufactured by chemical synthesis, extraction, cell 
culture/fermentation or by recovery from natural sources. Chemical synthesis has long 
been the most important route but biotechnology has been growing in importance as a 
sub-sector since the 1990s. In drug formulation, the active ingredient is combined 
with other inactive ingredients (excipients) in a physical transformation process 
involving activities such as granulation, drying, blending and compressing. 
 
The manufacture of active ingredients through chemical synthesis is a multi-stage 
process. Chemical ingredients are combined into new molecules in a number of 
chemical synthesis steps. The required inputs can be categorised into regulatory 
starting materials, basic raw materials and reagents. The regulatory starting materials 
are substantial fragments of the active ingredient molecule that are specified in the 
process filed with the regulatory authorities. They are specific to the product and 
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custom made. These are combined with the basic chemicals and reagents in several 
chemical transformations. The distinction between active ingredient and input 
production is flexible, depending on the number of steps the pharmaceutical company 
decides to conduct in-house or to out-source. The basic chemicals such as solvents are 
more general and are used by a variety of industries. The reagents are speciality 
chemicals that may be produced for use in particular types of chemical reaction by a 
large number of pharmaceutical companies. 
 
The other important route to manufacture active ingredients involves biotechnological 
processes. Advances in biotechnology have made it possible to genetically manipulate 
specific bacterial or mammalian cells that produce the required proteins. The 
manufacturing process of the active ingredient involves two steps: the growing of 
cells in bioreactors (the upstream process) and the subsequent separation/purification 
of the protein (the downstream process). The process involves a more limited amount 
of inputs, notably media, buffers and resins. Bio-fermentation is a frontier technology 
that typically involves relatively highly skilled personnel. 
 
Figure 3 charts employment growth in different sub-sectors of the pharmaceutical 
industry in Ireland. It shows that most employment growth was accounted for by the 
drug formulations sub-sector (drug products in the diagram) and the relatively higher 
value added active ingredients sub-sector (drug substance in the diagram). Very few 
companies manufactured other intermediates (van Egeraat, 2006).  
 
5.1 Active Ingredients 
 
The multinational pharmaceutical firms that invested in Ireland in the 1960s and 
1970s were models of Fordist industrial organisation that was associated with a 
distinct geography of production and R&D (Malecki, 1997; Hayter, 1998; Dicken, 
2007). The geography of production was characterised by a decentralisation of 
manufacturing functions. Companies established branch plants in numerous markets 
to overcome trade-barriers and to avail of local tax incentives. Until the 1990s, the 
typical active ingredients plant established by foreign pharmaceutical companies in 
Ireland was a high volume production plant, producing one or a limited number of 
active ingredients for a limited number of formulation plants. Typically a company 
would have started producing the product in one of the new-product-introduction-
plants, or launch plants, in its home country. The manufacturing process was typically 
fully developed and all process issues ironed out before the product was transferred to 
a high volume plant in Ireland. The main drivers for investment in Ireland included 
low corporation tax and relatively low wages, given that the labour force was 
sufficiently skilled. The low rate of corporation tax was particularly important for the 
manufacture of high-value active ingredients. Most major pharma companies invested 
in at least one overseas high volume active ingredients production plant in one of only 
three countries that offered a similar package of incentives: Ireland, Puerto Rico and 
Singapore. 
 
After the 1990s the flow of investment in API manufacturing capacity to Ireland 
continued unabated. The aggregate growth figures mask important qualitative changes 
in Ireland’s role, raising the level value creation. Notably an increase in launch 
activities, a focus on the later stages of the chemical synthesis cycle, and the 
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attainment of global manufacturing mandates. The rise of biotechnology gave rise to 
further qualitative changes.  
 
Increasing role in launch activities 
From a taxation perspective it had always made sense to establish launch plants and 
begin production of new chemical entities in Ireland. However, launch plants and the 
related process development activities require relatively high skills that were not 
available initially in sufficient quantities. This situation changed over the course of the 
last two decades. Partly in response to the recognised requirements of the 
pharmaceutical industry, the Irish Government invested significant resources to 
increase the output of graduates with relevant skills. This allowed for a gradual shift 
of launch manufacturing (and related process development activities - see next 
section) to plants in Ireland. Many production sites in Ireland became responsible for 
both new product introductions and high volume production. 
 
This development coincided with changes in the industry’s technological and 
competitive environment. The number of diseases that can be targeted with 
chemically derived pharmaceuticals is limited and during the 1990s the number of 
potential blockbuster drugs in the pipeline of the traditional pharmaceutical 
companies fell sharply. Companies are increasingly relying on smaller volume high-
value drugs for niche markets, and new versions of existing drugs, e.g. for new 
indications. This increased the amount of new product introductions and the need to 
for “flexible” multi-product launch plants, as opposed to mono-product plants 
designed for the synthesis of a specific active ingredient 
 
Focus on the last stages of the chemical synthesis cycle 
In addition, in a global context characterised by reduced rates of revenue growth and 
increasing costs (see van Egeraat, 2008), an increasing number of companies began to 
outsource non-core activities. Although the strategies differ, some companies have 
started to outsource the early steps of the active ingredient synthesis cycle. Moving 
back into the synthesis chain, the regulatory requirements tend to be lower and, as a 
result, skill requirements and the required level of control over the production process 
diminish. Some companies have outsourced these early stages to fine chemical 
suppliers that have been assuming an increased role in the production of regulatory 
starting materials. There is some evidence of a cyclical element in the outsourcing 
pattern.  At the early stage of the product life cycle, companies add significant value 
to the product by using their technology recourses to optimise the production process. 
Later, when the marginal benefits of further continuous improvement activities 
decline and the product moves closer to the end of its patent-protected period, 
companies start to outsource the mature product, thereby also freeing up capacity for 
new product introductions. 
 
Ireland`s rapidly rising wage levels of the Celtic Tiger era provided an extra incentive 
to use the Irish facilities for the higher value added elements in the manufacturing 
chain, notably for new product introductions and late stage synthesis.   
 
Very few processes are outsourced to companies in Ireland. Traditionally the basic 
chemicals and fine chemical supplies were imported from suppliers in the UK and 
Europe. Over the last decade however, the pharma companies have increasingly used 
low-cost suppliers in India and China, though mainly for lower value added supplies. 
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The interviews suggest that some pharma companies remain hesitant to outsource the 
later stage synthesis to companies in India and China, doubting whether these 
companies have the requisite technical knowledge and can meet the health and safety 
standards required to supply the highly regulated EU, Japanese and North American 
markets. In addition pharma companies are concerned that disclosed intellectual 
property may not be protected. This perception is changing however and pharma 
companies have even begun to contemplate setting up their own API plants in China 
and India. 
 
 “We are now going through an internal discussion. Do we maintain that 
[production of a particular product in house] going forward or do we go to 
India and China and outsource those products? And we are now starting to 
do more of that than we have done in the past. Mainly active ingredients 
right now […] a product that would go off patent. So we are using some of 
these compounds as the vehicles to test that methodology” (interview 
general manager API plant). 
 
Global manufacturing mandates 
Another qualitative change in Ireland’s role concerns a widening of the manufacturing 
mandates to cover global markets. Since this development is even more significant in 
the context of drug formulation activities, a full discussion will be included in the next 
section. The main difference between active ingredients and drug formulation is that 
active ingredient plants, given their capital intensive nature, have always had relative 
wide mandates. Geographical strategies are idiosyncratic but it is generally true to say 
that until the 1990s some of the larger firms tended to organise their active plants on a 
supra-regional basis, with the Irish active ingredient plants supplying European 
formulation plants.  Many of these companies have since adopted a global supply 
strategy and Irish API plants have become the single global source for a range of 
companies’ active ingredients.  
 
Increase in biopharmaceutical fermentation activity 
Finally, since 2000 Ireland is emerging as an increasingly important location for 
biopharmaceutical active ingredient plants (Van Egeraat, 2006). The rise of 
biotechnology, besides introducing a new high-tech production activity to the Irish 
pharmaceutical space, has also changed Ireland’s relative role in global manufacturing 
networks.  
 
Biotechnology is still a frontier science and the production of active ingredients 
requires highly skilled staff – even more skilled than in the case of chemical synthesis. 
In addition, biofermentation requires a greater process R&D effort, a substantial 
amount of which needs to take place at the site of the commercial manufacturing 
plant, which further increases skill requirements. By way of illustration, nearly 60 per 
cent of all staff at one of the interviewed biopharmaceutical active ingredient plants 
had third level degrees. The number of locations that can satisfy these skill 
requirements is more limited than in the case of chemical synthesis. In most cases, the 
Irish facility is one of only one or two facilities outside a company’s home country, 
making it a strategic facility supplying global markets from the start. Although most 
of the Irish facilities are established to provide additional capacity for existing 
products, the intention is that the plants will begin to act as new product introduction 
plants as soon as new molecules emerge from the the development pipeline. The 
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technology and skills requirements mean that at this point in time Ireland competes 
for inward investment projects with other technologically advanced locations, 
including Switzerland, rather than with low cost economies. “… at this point in time 
you would not be looking at China and India for this type of investment” (Interview 
with general manager of biopharmaceutical active ingredient plant). The required 
inputs – mainly media, buffers and resins – tend to be exclusively sourced from 
technologically-advanced locations in the USA, Europe and Japan. 
 
5.2 Drug Formulations 
 
The drug formulations sub-sector has experienced strong growth, particularly since 
the 1990s. Here too the absolute growth in formulation activity was accompanied by 
important qualitative changes in Ireland’s involvement in global manufacturing 
networks, notably a widening of product mandates to cover European and global 
markets. Traditionally, tariff and regulatory non-tariff barriers meant that 
pharmaceutical companies operated separate formulation plants in many different 
countries (Jungmittag and Reger, 2000). The development of the EU single market 
and new WTO agreements led to increasing harmonisation of regulatory regimes and 
a reduction of other non-tariff barriers impinging on international trade in 
pharmaceutical products. The expectation was that the development would lead to a 
global rationalisation of formulation plants (Howells, 1992). 
 
Although we have no global data indicating the extent of this rationalisation, it is 
known that several companies comprehensively reorganised their manufacturing 
organisation (Forfas, 1995, EFPIA, 2003). These companies concentrated production 
in fewer super-manufacturing plants, although even after the rationalisation most 
companies still retained a significant amount of formulation plants in different 
markets, partly due to the fact that significant non-tariff barriers persisted (White, 
2000a). 
 
Ireland was strongly positioned to benefit from this trend. First, due to the small size 
of its market, Ireland never had had much leverage over pharma companies to 
establish small local market-oriented plants. As a result there were relatively few 
small-scale inefficient plants to rationalise and many plants already served export 
markets. Secondly, the attractive taxation regime, low labour costs and the presence of 
sufficiently skilled labour made Ireland an attractive location for consolidated 
manufacturing operations. The classic example in Ireland is the Wyeth Medica plant 
in Newbridge. As part of a global restructuring process, this plant was established to 
consolidate the formulation activities of 13 manufacturing plants in Europe that had 
been closed down. The Irish facility is one of the company`s two ‘strategic’ 
formulation plants (the other one is located in Puerto Rico) producing a large number 
of products, often for world markets. An indication of the trend towards global supply 
mandates is that 31 out of about 80 pharma plants that operated in Ireland in 2006 
were approved to supply the US market (Interview IDA; see also Irish Times, July 2, 
2004). 
 
Besides this widening of the geographical product mandates, some of the qualitative 
changes discussed under active ingredients are applicable to formulation 
manufacturing, though not always to the same extent. Many formulation plants have 
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obtained launch plant status and are thus responsible for the relatively skill-intensive 
new-product introductions (and related process development activities - see below).  
The strategic nature and know-how, in combination with now higher labour costs,  
mean that the plants tend to be used for the most value-added markets and stages in 
the product life-cycle. Many plants focus on the introduction of new products. Nearer 
to patent expiry the same products are outsourced or left to the specialised generics 
companies. In addition, the plants in Ireland tend to focus on the more regulated, more 
technology-intensive, and therefore higher value-added markets, notably the USA and 
EU. “They [some of the formulation plants in low cost locations] are low cost 
operations, serving the local market. They would not have the capacity or 
sophistication to supply into Europe or US. For us to supply those small markets from 
this plant would be a distraction. Our primary focus is Europe and US” (interview 
general manager, formulation plant).  
 
As to the competition from other locations, while most companies have production 
plants in Eastern Europe, India and China to supply the local markets, the 
interviewees still consider these countries substantially less attractive than Ireland as a 
location for the formulation of patented drugs for the strongly regulated markets such 
as the EU and USA. However, as in the case of active ingredients, interviewees 
typically contend that the growing capability in these regions, in combination with 
rising costs in Ireland, have the potential to jeopardize Ireland’s position in the 
medium term. 
 
6. Research and Development 
 
The Fordist geography of R&D differed from that of production. On an international 
level, the R&D functions of multinational companies, particularly the more strategic 
activities, remained firmly located in the companies` home countries. Some 
decentralisation of R&D occurred, but such units were typically small and limited to 
short-run adaptations of mature products (Hayter, 1998). Until the 1980s, the 
pharmaceuticals sector followed this locational model closely, with basic research 
functions conducted in the central research units located near the head-offices and 
main production sites of the companies. Branch plants frequently housed small 
technical and development units, but the scope of such activities was limited 
(Howells, 1984). Even in the case of process R&D, the manufacturing process was 
typically for the most part developed by the central R&D group located near the head-
office and then transferred to the manufacturing function and manufacturing sites.  
 
This model of R&D involved inherent structural and operational inefficiencies. 
Growing competitive and commercial pressures in the post-Fordist period have forced 
firms to address these inefficiencies resulting in a significant reconfiguration of the 
spatial organisation of R&D. The following sections analyse Ireland’s changing role 
in three of the main components of pharmaceutical-industry R&D, namely discovery, 
clinical development and process development.  
 
6.1 Discovery 
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The discovery stage is concerned with research into the causes of diseases and the 
identification of compounds relevant to particular diseases. A large number of these 
leads are assessed for their biological activity. The discovery stage ends with the 
selection of one or a small number of drug candidates that are believed to have the 
potential for further development. 
 
In the face of renewed competitive pressures and technological change, 
pharmaceutical companies have profoundly reorganised their discovery functions. 
Although most of the discovery research is still done in the laboratories of the 
companies` home countries (Agrawall 1999), discovery activities have become truly 
international. In addition, firms increasingly rely on external sources of knowledge, 
notably dedicated biotechnology firms. Apart from the establishment of overseas 
R&D laboratories, the internationalisation process takes many other routes such as the 
establishment of alliances and joint ventures between large pharmaceutical 
companies, R&D co-operation and licensing agreements with dedicated 
biotechnology firms, pre-competitive research collaboration with universities, and the 
financing of university research (Reger, 2000). As regards their internal R&D 
activities, most large pharmaceutical companies have now created globally integrated 
networks of research units, often specialised in a particular disease or technology 
(centres of excellence). Although strongly internationalised, the discovery research 
units are highly concentrated in a relatively small number of countries (Taggart, 1993; 
Schweitzer, 1997; Lane and Probert, 2004) and, within these, in a small number of 
global “megacentres” that offer important pools of specialised skills and facilitate 
knowledge exchange (Cooke, 2002; Zeller, 2004)  
 
The internationalisation of discovery has largely by-passed Ireland. In 1999, there was 
little or no drug discovery conducted in Ireland (ICSTI, 1999) and this situation has 
changed little. None of the 11 multinational companies interviewed for this research 
had a formally constituted discovery laboratory in Ireland. All companies had 
multiple discovery laboratories in several countries. All had one or more discovery 
laboratories in the USA, while eight had at least one laboratory in the UK. The main 
second tier locations included Switzerland (3 companies), France (3) and Spain (3). 
 
The IDA never targeted the large-scale discovery laboratories. It was not considered a 
realistic option because, until recently, the relevant science and technological 
infrastructure in Ireland was poor by international standards. In 1999 there were no 
world class universities or centres of excellence and university-industry co-operation 
was superficial, short-term and under-funded (ICSTI, 1999). This situation has 
changed profoundly since 2000 when the Irish Government started to invest heavily in 
the national science and technology infrastructure. Science Foundation Ireland has 
funded a large body of academic researchers and research teams involved in basic 
research, notably in the field of biotechnology. These developments are unlikely to be 
sufficient to attract large scale discovery units of multinational companies however. 
The pharmaceutical companies interviewed rated the chance of the company 
establishing discovery functions in Ireland as low or very low. 
 
Although not sufficient to attract large scale discovery units of multinational 
companies, the upgraded science base has increased Ireland’s role in the 
internationalised discovery networks of the pharmaceutical industry in an indirect 
way. Through the SFI-funded university-industry collaborations known as Centres of 
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Science Engineering and Technology (CSETs), several Irish universities are now 
directly co-operating with international pharmaceutical companies in basic research 
projects. In addition, more recently, the IDA has recognised that the upgraded 
technology base provides a new opportunity for attracting foreign investment in 
applied research, and a small number of multinational pharmaceutical companies are 
now directly employing staff, integrated in applied research groups at Irish 
universities. Finally, the growing body of Irish scientists, in combination with start-up 
funding provided by Enterprise Ireland, has resulted in the growth of indigenous 
campus and start-up companies in the area of pharmaceuticals and biotechnology. A 
small number of these research-focussed companies has established collaboration 
agreements with major pharmaceutical companies. Although these developments are 
encouraging, the number of start-up companies that have brought products to clinical 
trials stage is small, and Ireland’s involvement in drug discovery in general remains 
limited by international standards. 
 
6.2 Clinical Trials 
 
Clinical studies involve the testing and evaluation of new drug candidates on human 
subjects in randomised controlled trials. The core activities include the collection, 
management and analysis of highly codified clinical data as well as project 
management and support.  Due to increasingly stringent regulatory requirements, 
clinical studies can now take between 6 and 10 years, depending on the therapeutic 
area, and have become the greatest cost factor in bringing a new drug to market 
(Chiesa, 1996; Reger, 2000; Schofield, 2001).  
 
The clinical trials process is typically organised through a three-tiered structure. The 
product team within the pharmaceutical firm integrates the trial results into the drug 
development plan. Secondly, the clinical monitors project-manage the trials and 
oversee the quality of the data. Clinical monitoring mainly concerns the routine 
manipulation, storage, and transfer of codified data, though the monitors also have a 
role in problem identification and mediating disputes. Finally, the group of clinical 
investigators enrol patients into the study and oversee test patients at the clinic 
(Azoulay, 2003).  
 
A large part of the actual data collection activity takes place in a variety of clinics 
whose work is financed by the pharmaceutical companies. Many hospitals have 
developed dedicated centres to facilitate clinical trials work. The clinical monitoring 
activities were traditionally conducted by the pharmaceutical company`s clinical 
operations group, and large companies continue to operate a number of clinical 
research units located in different parts of the world. However, since the 1980s the 
monitoring and data management activities have been increasingly outsourced to 
specialised Clinical Research Organisations (CROs). These CROs are typically 
involved in the operational aspects of the study with little or no input into the more 
knowledge-intensive elements of the monitoring activities. As such the CROs have 
been characterised as “data sweatshops”, and their employees as “data mules”. 
(Azoula, 2003) 
 
Clinical trials have been identified as an important opportunity to increase Ireland’s 
involvement in high value added activities in the pharmaceutical industry, (Enterprise 
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Strategy Group, 2004; Forfás, 2003; ICSTI, 2003) and IDA Ireland is specifically 
targeting this segment. Recently, a number of universities established the Irish 
Clinical Research Network in an attempt to fill the gaps in Ireland’s clinical research 
infrastructure. Until now the efforts have had limited success and clinical trials remain 
under-represented in Ireland (Forfás, 2003; Brennan, 2008). Apart from the dedicated 
clinical research centres connected to major hospitals (Beaumont, St. James, 
Vincent’s), direct investment by the private sector has been extremely limited. 
Exceptions include the clinical research unit of Merck in Dublin and a small number 
of subsidiaries of international CROs, notably Quintiles. 
 
A number of factors are important in a company’s location decision for clinical trials, 
inter alia: the importance of the market for the drug; a high willingness and ability to 
cooperate on the part of professional clinics and doctors; strong cooperation with the 
national approval authorities; efficiency of the ethics commissions involved; and 
costs, quality and time performance (Reger, 2000). The creation of a pan-European 
clinical research market and unified legal environment (Samsonov, 2005) have to 
some extent reduced Ireland’s disadvantage in terms of market size although the 
increasingly important pan-European regulatory authorities are located outside Ireland 
(Reger, 2000). However, according to one interviewee at a clinical trials unit, a new 
obstacle for Ireland is that it has become increasingly difficult and expensive to recruit 
test volunteers.  
 
 
6.3 Process R&D 
 
After the identification of a new target molecule in product development, process 
R&D is responsible for the development of safe and efficient manufacturing processes 
of commercial scale. The process R&D cycle of the pharmaceutical industry is 
complex and involves a number of integrated activities. The various stages of the 
cycle are listed in Table 6, starting with pre-formulation studies and ending with 
continuous improvement and the development of generation processes. A detailed 
discussion of the various activities is beyond the scope of the present paper. For the 
present discussion it is important to point out that, although all stages can involve 
skilled and highly educated staff, the early stages in the cycle involve the greatest 
number of, and the most highly-skilled, researchers. In addition, companies generally 
aim to have made most major decisions regarding the process prior to phase III 
clinical trials (activity 7 and 8 in Table 6). From here on, process development 
focuses on the final details of the process.  
 
Until the mid-1980s, under the Fordist regime, branch plants frequently housed small 
technical and development units that had some role in process development, but the 
scope of such activities was limited (Howells, 1984). Typically, the manufacturing 
process was for the most part developed by the central R&D group located near the 
head-office and then transferred to the manufacturing sites.  
 
Van Egeraat (2007) shows that since the mid-1980s the role of Ireland in the global 
process R&D networks of multinational pharmaceutical companies has changed. The 
survey of pharmaceutical firms showed that in the period 2000-2006, the number of 
 17
people involved in process R&D almost doubled, from 408 to 800, compared with a 
36 per cent growth rate in total employment over the period.  
 
To get an insight into the relative role of the Irish plants in the global networks of 
their parent firms, survey respondents were asked to rate the input of the local staff in 
various process R&D activities of the parent firm on a seven-point Likert scale (where 
a score of 1 indicated that the Irish plant had no input in the activity and a score of 7 
indicated that the Irish plant had sole ownership of the activity in question). The 
findings of this question are presented in Table 6. The columns represent the 
proportion of relevant establishments falling into each Likert scale score category 
while the “mean” column indicates the mean score obtained for all respondent 
establishments for the relevant R&D activity 
 
Overall the data clearly show that the involvement of the Irish staff in process R&D 
only becomes substantial after the proof-of-concept point, at the start of phase III 
clinical trials. As mentioned earlier, this is the point at which companies generally 
want to have locked down the process parameters. From here on process R&D 
activities focus on the final details of the process and technology transfer. The fact 
that the Irish establishments tend to concentrate their involvement in process R&D 
activities in the later stages of the cycle does not mean that they are involved in low-
skilled or mundane activities. The education profile of staff involved in process R&D 
can be used as an indicator of the quality or sophistication of the activities carried out 
in the Irish subsidiaries. The survey shows that process R&D activities in the Irish 
pharmaceutical sector employ a substantial number of highly- skilled people, with 30 
per cent of the 800 people involved holding a PhD degree as their highest level of 
academic attainment, with 19 per cent having a Masters degree, and a further 46 per 
cent holding a primary degree.  
 
The change in Ireland’s role in process R&D activities is the result of several partly 
integrated drivers (Van Egeraat and Breathnach, 2008). First, reacting to increasing 
costs of developing new products alongside pressure on drug prices and revenues, 
pharmaceutical companies have begun to organise their process development function 
more effectively. The required co-ordination between the various stages of the process 
development cycle and between process development and manufacturing functions 
has been achieved by co-locating selected process R&D functions at manufacturing 
plants, including in Ireland.  Another important driver lies in the international taxation 
regime, notably the introduction in the mid-1990s of U.S. legislation for Cost-Sharing 
Arrangements for developing intellectual property. This provided an instrument for 
US multinationals to share the costs of developing intellectual profits between various 
subsidiaries, and thereby shift some of the profits to subsidiaries in lower-tax 
jurisdictions, including Ireland. The location in Ireland of functions additional to 
manufacturing, notably R&D pilot plants, could be used to justify higher levels of 
value added and profits attributed to the Irish subsidiaries. Finally, a number of 
measures implemented by the Irish Government in recent years have also exerted a 
positive influence on the disposition of pharmaceutical MNEs towards locating 
process R&D activities in Ireland without necessarily being a key driver, namely:  the 
investment in education and the resulting rapid growth in the supply of science and 
technology graduates discussed earlier; the major expansion of state funding of 
scientific research; tax credits for R&D expenditure and grant schemes to support 
R&D initiatives. 
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7. Conclusion 
 
Mainly driven by foreign direct investment, employment and export levels of the Irish 
pharmaceutical industry have grown substantially over recent decades, and Ireland has 
become one of the main pharmaceutical exporters. The growth continued after 2002, 
at a time when most other manufacturing sectors in Ireland experienced decline. 
This growth is positive in itself, particularly in light of the fact that the pharmaceutical 
sector is one of the most skill-intensive manufacturing sectors in Ireland. But from a 
dynamic regional development perspective it is also interesting to explore the 
qualitative changes in the types of activities that are conducted in Ireland. Adopting a 
global production network approach for examining regional development in the 
context of globalisation, the paper examined Ireland’s changing role in global 
production networks within the pharmaceutical industry, focussing on the different 
components of manufacturing (i.e. active ingredients and drug formulations) and 
R&D (i.e. discovery, clinical trials and process development).  
Within manufacturing, there has been very little growth in the (relatively) low value 
generating activity of basic chemicals. Employment growth instead occurred mainly 
in drug formulation and the higher-value-generating active ingredients sub-sector. 
Alongside this, Irish plants have assumed a greater role in launch activities, an 
increased focus on the later stages of the chemical synthesis cycle, and a geographical 
widening of product mandates. All these developments have substantially increased 
the level of value creation  
 
Ireland’s role in R&D differs considerably from activity to activity. Notwithstanding 
recent developments in Irish third-level institutions and the growing number of 
indigenous research-based companies, Ireland’s relative role in the high value 
generating drug discovery field remains very limited. Similarly, in spite of efforts to 
upgrade the necessary infrastructure, high value generating clinical trials activities 
remain under-represented in Ireland. Finally, Ireland’s role in the medium value 
generating process R&D activities has increased substantially, with a doubling of the 
number of people involved over the period 2000-2006. Even in this area however, 
Ireland’s involvement is concentrated in the (relatively) lower value generating down-
stream phases of the cycle. 
 
Although the picture is complex and differentiated, the level of value creation in the 
Irish pharmaceutical industry has increased substantially over the Celtic Tiger era. In 
spite of an increasing number of indigenous research-focused start-up companies 
however, the sector remains strongly dominated by foreign direct investment so that a 
large share of the value is not captured within Ireland.  
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Figure 1. Employment in pharmaceuticals (NACE 257) in Ireland, 1979-1991 
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Source:  Census of Industrial Production (various issues) 
Note: CIP (1991) yields employment numbers for both NACE 257 and NACE 244 for that year 
 
Figure 2. Employment in pharmaceuticals (NACE 244) in Ireland, 1991-2005 
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Source:  Census of Industrial Production (various issues) 
 
Figure 3. Employment pharmaceutical industry by sub-sector 1972-2003 
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Source: Van Egeraat, 2006 – using Forfás Employment Survey 
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Table 1.  Share of pharmaceutical sector in manufacturing employment, 1985-
2000, various countries  
 1985 1990 1995 2000 2005 
European Union (15 countries) 1.5 1.7 2 2  
Belgium   2.1 2.6 3.3 
Denmark 2.3 3.1 3.7 2.7  
Germany 1.2 1.3 1.6 1.7 1.7 
Ireland 1.3 1.9 2.6 3.4 5.2 
Greece 2 2.3 2.4 1.7  
Spain 1.6 1.6 1.8 1.4 1.5 
France 2 2.5 2.7 3 2.8 
Italy 2 2.3 1.4 1.5 1.5 
Netherlands 1.7 1.6  2  
Austria   1.4 2 1.6 
Portugal  0.9 0.9 0.8  
Finland  0.9 1.5 1.4 1.0 
Sweden  1.5 2.2 2.8  
United Kingdom 1.3 1.5 2 2.1* 2.1 
United States 0.9 1 1.3   
Japan 0.9 0.9 1   
Source: Eurostat Annual Enterprise Statistics 
Note: the 1985-2000 figures refer only to enterprises employing 20 or more persons 
* refers to 2001; blank cells indicate data not available. 
 
 
Table 2.  Third-level graduates as share of sectoral employment, 2006 
 
Third-Level 
Graduates as 
Share of 
Sectoral 
Employment   
Third-Level 
Graduates with 
degree or higher as 
Share of Sectoral 
Employment   
Manufacturing industries 32.8 19.9 
Food industries 23.4 14.2 
Beverages and tobacco 42.5 27.9 
Textiles, clothing, footwear and leather 18.9 9.9 
Wood and wood products 17.3 9.1 
Paper, paper products, printing and publishing 35.9 21.8 
Chemical, rubber and plastic products 45.7 31.2 
Glass, pottery and cement 18.6 10.0 
Metals, metal products, machinery and engineering 36.6 21.8 
Other manufacturing (incl. transport equipment) 21.6 10.5 
Source: Population Census 2006, Volume 10: Education and Qualifications; Table 8. 
 
 25
 
Table 3.  Wages per head by industrial sector 
Sector 
2004 
Wages per Head, € 
Manufacturing Industries 32,126 
Food Beverages and Tobacco 31,493 
Textiles 23,382 
Clothing 22,315 
Leather 21,575 
Wood and Wood Products 25,660 
Pulp and Paper 35,257 
Publishing 35,325 
Chemicals 39,498 
          of which: Pharmaceuticals 38,883 
Rubber and Plastics 27,660 
Non-Metallic Minerals 30,099 
Basic and Fabricated Metals 28,196 
Machinery and Equipment nec. 29,361 
Office Machinery and Computers 35,714 
Electrical machinery 29,805 
Radio, TV, and Medical Devices 31,382 
Transport Equipment 33,472 
Manufacturing nec and Fuels 26,407 
Source: Census of Industrial Production, Manufacturing Local Units 
 
Table 4.  Country shares of global pharma exports, 1965-2005; selected countries 
 1965 1970 1975 1980 1985 1990 1995 2000 2005 
Ireland 
0.6 
 
0.7 
 
1.2 
 
1.2 
 
1.2 
 
2.7 
 
3.2 
 
4.5 
 6.6 
Japan 
2.0 
 
2.1 
 
1.6 
 
2.1 
 
2.3 
 
2.5 
 
1.5 
 
2.0 
 
1.0 
 
USA 
15.3 
 
13.2 
 
11.5 
 
14.4 
 
16.7 
 
11.9 
 
8.2 
 
11.4 
 
8.7 
 
UK 
11.3 
 
10.5 
 
10.8 
 
12.3 
 
11.1 
 
11.5 
 
12.1 
 
11.1 
 
8.6 
 
Switzerland 
10.9 
 
10.3 
 
11.0 
 
11.4 
 
9.6 
 
12.4 
 
10.7 
 
9.1 
 
9.0 
 
Italy 3.6 4.8 5.0 4.9 5.1 4.3 4.1 5.9 4.7 
France 8.2 7.2 8.3 10.6 9.2 10.4 10.4 10.2 8.8 
Germany 27.6 30.7 27.8 16.1 14.2 16.7 14.8 12.7 14.6 
Netherlands 8.4 4.4 4.3 4.4 3.6 3.9 5.4 4.1 4.1 
Belgium* 1.8 
2.6 
 4.1 4.7 4.0 4.6 7.2 7.4 
14 
 
Spain 
0.1 
 
0.4 
 
0.5 
 
1.4 
 
1.4 
 
1.8 
 
1.2 
 
1.8 
 
2.5 
 
Source: UN Comtrade database 
*: Belgium and Luxembourg until 1995; Belgium alone for 2000 and 2005. (Exports from Luxembourg 
are insignificant). 
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Table 5. Indications of possible transfer price manipulation in the Irish pharma 
sector, 2001 
  Gross Value Added per 
person employed 
(thousands of euro) 
Share of personnel costs in 
production 
Industry 
NACE 
codes 
EU15 UK Irl EU15 UK Irl 
Pharmaceuticals 24.4 106.3 141.1 251 18.5 20.1 7.2 
Source: Barry (2005) 
   
Table 6. Involvement of Irish establishments in process R&D activities   
 Likert scale score (% of establishments)*  
 
Process R&D activities 1 2 3 4 5 6 7 mean 
1 Pre-formulation studies. 74.6 6.8 0.0 1.7 5.1 3.4 8.5 2.0
2 Derivation of initial route / process options 
and preliminary evaluation 71.0 11.3 1.6 3.2 6.5 1.6 4.8 1.9
3 Evaluation in small scale experiments 63.9 13.1 3.3 3.3 4.9 1.6 9.8 2.2
4 Evaluation in kilo lab 62.1 10.3 5.2 1.7 5.2 6.9 8.6 2.3
5 Production for Phase II clinical trials 52.8 13.2 5.7 5.7 7.5 1.9 13.2 2.6
6 Evaluation and optimisation in pilot plant 
prior to Phase III clinical trials 39.6 17.0 17.0 7.5 5.7 5.7 7.5 2.7
7 Production for Phase III clinical trials 25.9 5.6 9.3 9.3 14.8 16.7 18.5 4.1
8 Evaluation and optimisation in pilot plant 
during Phase III clinical trials 27.8 9.3 14.8 7.4 16.7 13.0 11.1 3.6
9 Equipment design 9.7 9.7 11.3 14.5 19.4 19.4 16.1 4.5
10 Optimisation in commercial plant (pre filing) 4.8 3.2 3.2 6.5 16.1 21.0 45.2 5.7
11 Validation 0.0 0.0 3.2 4.8 6.5 22.6 62.9 6.4
12 Continuous improvement 0.0 1.6 0.0 1.6 9.7 21.0 66.1 6.5
13 Development of second generation process 
(outside filing parameters) 9.8 8.2 14.8 4.9 14.8 11.5 36.1 4.9
*Note: 1 = no input in activity by Irish plant; 7 = Irish plant has sole ownership of activity 
 
 
 
 
